| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 67.97 | 3.4% | 11.3% |
| Total Income | 67.97 | 3.4% | 11.3% |
| Expenditure | 50.28 | 0.6% | 23.4% |
| PBT | 19.67 | 11.4% | 12.8% |
| Net Profit | 15.02 | 11.9% | 13.5% |
| OPM | 26.03% | 2.95pp | 7.24pp |
| NPM | 22.10% | 2.12pp | 6.34pp |
| EPS | 0.66 | 12.0% | 14.3% |
LeMaitre Vascular Reports Q3 2026 Results, Announces Dividend, and Provides Guidance
05 Nov 2026 · 3d ago, 3:16 am
Summary
LeMaitre Vascular reported strong Q3 2026 results with sales reaching $68.0 million, an 11% increase year-over-year, driven by growth in grafts and shunts. The company maintained a healthy gross margin of 71.7% and saw adjusted operating income rise by 5% to $17.7 million, with adjusted EPS up 5% to $0.65. Management expressed confidence in achieving full-year sales growth of 11% and provided guidance for Q4 2026 and the full year, anticipating continued healthy sales and EPS growth.
Key Highlights
- 1
LeMaitre Vascular reported Q3 2026 sales of $68.0 million, an increase of 11% compared to Q3 2025.
- 2
The company achieved a gross margin of 71.7% in Q3 2026, up 90 basis points versus adjusted figures.
- 3
Operating income for Q3 2026 was $17.7 million, showing a 5% increase versus adjusted figures.
- 4
Diluted Earnings Per Share (EPS) for Q3 2026 was $0.65, up 5% versus adjusted figures.
- 5
Cash increased by $13.5 million sequentially to $390 million at the end of Q3 2026.
- 6
The company announced a quarterly dividend of $0.25 per share.
- 7
Full Year 2026 guidance projects sales between $274.8 million and $276.8 million, representing an 11% increase.
Management Comments
George LeMaitre
We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.
Informational and educational content only. Not investment advice.